Eaton Scientific has identified, developed and filed a patent for a novel indication of an existing FDA-approved drug, homatropine, for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal and post-menopausal women. The drug indication, that Eaton Scientific named Tropine 3, is currently being prescribed and compounded by doctors in Los Angeles, Calif., specifically for their patients who have hot flash symptoms and do not want to take hormonal treatment. The drug, homatropine, is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system. It is used in eye drops as a cycloplegic, and as a mydriatic in order to dilate the pupil. Homatropine is also given as an atropine substitute given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic administration. Homatropine has been prescribed continuously and safely in the U.S. for over 40 years.
The company currently is assembling a senior management team and group of scientific advisors to assist in the ongoing development and clinical testing of Tropine 3. Clinical trials will support claims made in Eaton Scientific's patent filed under USPTO #60/719,756.